Drug Policy Alliance DrugPolicy.org 5
1. Atwood, Brady K., John Huffman, Alex Straiker, and Ken Mackie.
“JWH018, a Common Constituent of ‘Spice’ Herbal Blends, Is a Potent
and Efficacious Cannabinoid CB 1 Receptor Agonist.” British Journal
of Pharmacology 160, no. 3 (2010): 585-93. https://doi.org/10.1111/j.1476-
5381.2009.00582.x.
2. Taura, Futoshi, Supaart Sirikantaramas, Yoshinari Shoyama, Yukihiro
Shoyama, and Satoshi Morimoto. “Phytocannabinoids in Cannabis
Sativa: Recent Studies on Biosynthetic Enzymes.” ChemInform 38, no.
47 (2007). https://doi.org/10.1002/chin.200747225.
3. “Drug Enforcement Administration’s National Forensic Laboratory
Information System NFLIS Home.” Drug Enforcement Administration’s
National Forensic Laboratory Information System NFLIS Home.
Accessed June 09, 2016. https://www.nflis.deadiversion.usdoj.gov/.
4. “UR-144 (TCMP-018; KM-X1) and XLR11 (5-F-UR-144).” Drug Enforcement
Administration, Office of Diversion Control: Drug & Chemical
Evaluation Section. May 2013. Accessed June 9, 2016. http://www.
deadiversion.usdoj.gov/drug_chem_info/spice/spice_ur144_xlr11.pdf.
5. “N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-
indazole-3- carboxamide (AB-CHMINACA), N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-pentyl- 1Hindazole-3-carboxamide (AB-PINACA)
and [1-(5-fluoropentyl)-1H-indazol-3- yl](naphthalen-1-yl)methanone
(THJ-2201): Background Information and Evaluation of ‘Three Factor
Analysis’ (Factors 4, 5, and 6) for Temporary Scheduling “ Drug
Enforcement Administration, Office of Diversion Control: Drug
& Chemical Evaluation Section. December 2014. Accessed June
9, 2016. https://www.grassley.senate.gov/sites/default/files/news/
upload/3- factor%20analysis%20AB-CHMINACA%20AB- PINACA%20
THJ2201%2012172014.pdf.
6. “AB-FUBINACA” Drug Enforcement Administration, Office of Diversion
Control: Drug & Chemical Evaluation Section. April 2014. Accessed
June 9, 2016. http://www.deadiversion.usdoj.gov/drug_chem_info/
spice/ab_fubinaca.pdf.
7. Fantegrossi, William E., Jeffery H. Moran, Anna Radominska-Pandya,
and Paul L. Prather. “Distinct Pharmacology and Metabolism of
K2 Synthetic Cannabinoids Compared to Δ9-THC: Mechanism
Underlying Greater Toxicity?” Life Sciences 97, no. 1 (2014): 45-54.
https://doi.org/10.1016/j.lfs.2013.09.017.
8. Winstock, Adam R., and Monica J. Barratt. “Synthetic Cannabis: A
Comparison of Patterns of Use and Effect Profile with Natural
Cannabis in a Large Global Sample.” Drug and Alcohol Dependence
131, no. 1-2 (2013): 106-11. https://doi.org/10.1016/j.drugalcdep.2012.12.011.
9. Missing
10. Missing
11. Missing
12. Missing
13. Missing
14. Missing
15. Missing
16. Missing
17. Missing
18. Missing
19. Walton, Alic G. “Why Synthetic Marijuana Is More Toxic To The Brain
Than Pot.” Forbes. August 28, 2014. Accessed June 09, 2016. http://
www.forbes.com/sites/alicegwalton/2014/08/28/6-reasons-synthetic-
marijuana-spice-k2-is-so-toxic-to-the-brain/#1db656f849eb.
20. Griffiths, Paul, Roumen Sedefov, Ana Gallegos, and Dominique Lopez.
“How Globalization and Market Innovation Challenge How We Think
about and Respond to Drug Use: ‘Spice’ a Case Study.” Addiction 105,
no. 6 (2010): 951-53. https://doi.org/10.1111/j.1360-0443.2009.02874.x.
21. Vandrey, Ryan, Kelly E. Dunn, Jeannie A. Fry, and Elizabeth
R. Girling. “A Survey Study to Characterize Use of Spice
Products (synthetic Cannabinoids).” Drug and Alcohol
Dependence 120, no. 1-3 (2012): 238-41. https://doi.org/10.1016/j.
drugalcdep.2011.07.011.
22. “Synthetic Cannabinoids.” Synthetic Cannabinoids.
Accessed June 09, 2016. http://www.aapcc.org/alerts/
synthetic-cannabinoids/.
23. “Update: Drug-Related Emergency Department Visits
Involving ...” Accessed June 9, 2016. http://www.samhsa.gov/
data/sites/default/files/SR-1378/SR- 1378.pdf.
24. Campos, A. C., F. A. Moreira, F. V. Gomes, E. A. Del Bel, and
F. S. Guimaraes. “Multiple Mechanisms Involved in the
Large-spectrum Therapeutic Potential of Cannabidiol in
Psychiatric Disorders.” Philosophical Transactions of the
Royal Society B: Biological Sciences 367, no. 1607 (2012):
3364-378. https://doi.org/10.1098/rstb.2011.0389.
25. Auwärter, Volker, Sebastian Dresen, Wolfgang Weinmann,
Michael Müller, Michael Pütz, and Nerea Ferreirós.
“‘Spice’ and Other Herbal Blends: Harmless Incense
or Cannabinoid Designer Drugs?” Journal of Mass
Spectrometry J. Mass Spectrom. 44, no. 5 (2009): 832-37.
https://doi.org/10.1002/jms.1558.
26. “Synthetic Cannabinoids and ‘Spice’ Drug Profile.” EMCDDA.
Accessed June 09, 2016. http://www.emcdda.europa.eu/
publications/drug-profiles/synthetic- cannabinoids.
27. “Notes from the Field: Increase in Reported Adverse Health
Effects Related to Synthetic Cannabinoid Use — United
States, January–May 2015.” Centers for Disease Control
and Prevention. 2015. Accessed June 09, 2016. http://www.
cdc.gov/mmwr/preview/mmwrhtml/mm6422a5.htm?s_
cid=mm6422a5_ w.
28. “Overdose Death Rates.” National Institute on Drug Abuse
(NIDA). 2015. Accessed June 09, 2016. https://www.drugabuse.
gov/related-topics/trends- statistics/overdose-death-
rates.
29. Zimmermann, Ulrich S., Patricia R. Winkelmann, Max
Pilhatsch, Josef A. Nees, Rainer Spanagel, and Katja Schulz.
“Withdrawal Phenomena and Dependence Syndrome After
the Consumption of “Spice Gold”” Deutsches Ärzteblatt
International. 2009. Accessed June 09, 2016. https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC2719097/.
30. Substance Abuse and Mental Health Services
Administration, Drug Abuse Warning Network, 2011: National
Estimates of Drug-Related Emergency Department
Visits. HHS Publication No. (SMA) 13-4760, DAWN Series
D-39. Rockville, MD: Substance Abuse and Mental Health
Services Administration, 2013.
31. “Monitoring the Future Study: Trends in Prevalence of
Various Drugs.” National Institute on Drug Abuse (NIDA).
Accessed June 09, 2016. https://www.drugabuse.gov/trends-
statistics/monitoring-future/monitoring-future- study-
trends-in-prevalence-various-drugs.
32. “MTF Data Tables and Figures.” MTF Data Tables
and Figures. Accessed June 09, 2016. http://
monitoringthefuture.org/data/15data.html#2015data-
drugs.
END NOTES